Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Stopped PI decision
Conditions
- Advanced Malignant Neoplasm
- ALK Fusion Protein Expression
- ALK Gene Amplification
- ALK Gene Mutation
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Neoplasm in the Central Nervous System
- Metastatic Malignant Solid Neoplasm
- ROS1 Fusion Positive
- ROS1 Gene Amplification
- ROS1 Gene Mutation
Interventions
- DRUG: Brigatinib
- OTHER: Laboratory Biomarker Analysis
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
Sponsor
Sameek Roychowdhury
Collaborators